Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients

AIDS

Volumn 13, Issue 2, 1999, Pages 177-184

  Foudraine, Norbert A ^a,b,d   Hovenkamp, Egbert ^a   Notermans, Daan W ^a   Meenhorst, Pieter L ^c   Klein, Michèl R ^a   Lange, Joep M A ^a   Miedema, Frank ^a   Reiss, Peter ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HIV; Immune reconstitution; Immunity; Mycobacterial infection; Opportunistic infections; Protease inhibitor

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; MYCOBACTERIUM ANTIGEN; PHYTOHEMAGGLUTININ; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; INFLAMMATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM XENOPEI; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HUMANS; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM XENOPI;

EID: 0033010070     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902040-00005     Document Type: Article

References (45)

1. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333:1534-1539.
2. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333:1528-1533.
3. Kelleher AD, Carr A, Zuanders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-329.
4. Gulick RM, Mellors JW, Havlir DV, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-733.
6. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351:228-230.
7. Notermans DW, Jurriaans S, de Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998; 12:167-173.
8. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
9. Pakker NG, Notermans DW, de Boer R, et al. Biphasic kinetics of peripheral blood T-cells after triple combination therapy in HIV-1 infection: a composition of redistribution and proliferation. Nat Med 1998; 4:208-214.
10. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
11. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today 1997; 18:245-251.
12. Pakker NG, Roos MTL, van Leeuwen R, et al. Patterns of T cell repopulation, virus load reduction and restoration of T cell function in HIV-infected persons during therapy with different antiretrovirals. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:318-326.
13. Foudraine NA, Weverling GJ, van Gool I, et al. Improvement of chronic diarrhea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1998; 12:35-41.
14. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256-261.
15. Power C, Nath A, Aoki FY, Del Bigio M. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection. N Engl J Med 1997; 336:661-662.
16. Teófilo E, Gouveia J, Brotas V, da Costa P. Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy [letter]. AIDS 1998; 12:449.
17. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996; 25:1674-1675.
18. Hood S, Bonington A, Evans I, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors [letter]. AIDS 1998; 12:447-448.
19. Valdez H, Gripshover BM, Salata RA, Lederman MM. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy [letter]. AIDS 1998; 12:538.
20. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis 1997; 24:1023-1025.
21. Hurni MA, Böhlen I, Furrer H, Braathen LR. Complete regression of giant molluscum contagiosum lesions in an HIV-infected patient following combined antiretroviral therapy with saquinavir, zidovudine and lamivudine [letter]. AIDS 1997; 11:1784-1785.
22. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997; 11:261-262.
23. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 1997; 11:1300-1301.
24. Parra R, Leal M, Delgado J, et al. Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. Clin Infect Dis 1998; 26:218-219.
25. Mallal SA, James IR, French MAH. Detection of subclinical Mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine. AIDS 1994; 8:1263-1269.
26. Aquilina C, Viraben R. Unusual presentation of mycobacterial infection after antiviral treatment in AIDS. 6th European Conference on Clinical Aspects and Treatment on HIV Infections, October 11-15, Hamburg, Germany 1997 [abstract 751].
27. Phillips P, Zala C, Rouleau D, et al. Mycobacterial lymphadenitis: can highly active antiretroviral therapy unmask subclinical infection? 4th Conference on Retroviruses and Opportunistic Infections, Washington DC, January 22-26 1997 [abstract 351].
28. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-255.
29. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997; 11:1895-1896.
30. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443-1445.
31. Michelet C, Arvieux C, Aubert V, et al. Viral ocular involvement after initiation of antiprotease inhibitor therapy. 4th Conference on Retroviruses and Opportunistic Infections. Washington DC, January 22-26 1997 [abstract 315].
32. Mitchell SM, Youle MS, Membrey WL, Jones CD. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 350:588-590.
33. Cameron DW, Heath-Chiozzi M, Danner SA, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351:543-549.
34. van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol 1994; 49:157-168.
35. Horsburgh CR, Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:1332-1338.
36. Green JB, Sidhu GS, Lewin S, et al. Mycobacterium-avium-intracellulare: a cause of disseminated life-threatening infection in homosexuals and drug users. Ann Intern Med 1982; 97:539-546.
37. Inderlied CB, Kemper CA, Bermudez LEM. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6:266-310.
38. Chester AC, Winn WC: Unusual and newly recognized patterns of nontuberculous mycobacterial infection with emphasis on the immunocompromised host. In: Pathology Annual 21. Edited by Sommers SC, Rosen PP, Fechner RE. Norwalk: Appleton Century Crofts; 1986:251-270.
39. Tomioka H, Maw WW, Sato K, Saito H. The role of tumour necrosis factor-α in combination with interferon-γ or interleukin-1 in the induction of immunosuppressive macrophages because of Mycobacterium avium complex infection. Immunology 1996; 88:61-67.
40. Munk ME, Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Resp J 1995; 8(Suppl. 20):6685-6755.
41. Mutis T, Cornelisse YE, Ottenhoff THM. Mycobacteria induce CD4+ T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur J Immunol 1993; 23:2189-195.
42. Shafer RW, Sierra MF. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis 1992; 15:161-162.
43. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349:995-996.
44. Vento S, Garofano T, Renzini C, et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy [letter]. AIDS 1998; 12:116-117.
45. French MAH, Mallal SA., Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992; 6:1293-1297.